anemia%20-%20iron-deficiency
ANEMIA - IRON-DEFICIENCY
Anemia is a condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) and/or hematocrit (intact RBC in blood) making it insufficient to address the physiologic needs of the body.
Iron-deficiency anemia is the anemia that resulted from inadequate iron supplementation or excessive blood loss.
It is the most common nutritional disorder worldwide and accounts for more than half of anemia cases.
It is prevalent among preschool children and pregnant women.

Definition

  • A condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) or hematocrit (intact RBC in the blood) making it insufficient to address the physiologic needs of the body
  • Based on WHO, anemia is having hemoglobin concentration:
    • Men (>15 years old): <13 g/dL
    • Women (non-pregnant, >15 years old): <12 g/dL
    • Women (pregnant): <11 g/dL (declines to 0.5 g/dL in the 2nd trimester of pregnancy)
    • Children (12-14 years old): <12 g/dL
    • Children (5-11 years old): <11.5 g/dL
    • Children (6 months - 4 years old): <11 g/dL

Etiology

Causes of Anemia

  • Normocytic anemia when RBC morphology is unremarkable 
    • Blood loss - most common cause
    • Decreased RBC production due to low RBC production or destruction of precursors of RBC within the bone marrow, eg chronic disease
    • Increased RBC destruction, eg hemolysis
  • Macrocytic anemia wherein the RBC is larger than the nucleus of a small lymphocyte on a peripheral smear due to:
    • Megaloblastic causes: Folate and vitamin B12 deficiency, HIV infection, rare inborn errors of metabolism, myelodysplastic syndrome or congenital dyserythropoietic anemia
    • Nonmegaloblastic causes: Marked reticulocytosis, aplastic anemia, abnormal nucleic acid metabolism of erythroid precursors interfering with nucleic acid synthesis, abnormal RBC maturation, other causes such as Down syndrome, alcohol abuse, liver disease and hypothyroidism
  • Microcytic anemia when RBCs appear smaller due to the following pathologic processes:
    • Reduced iron availability/iron-deficiency anemia
    • Acquired disorders of heme synthesis, eg thalassemia 
    • Reduced globin production
    • Rare congenital disorders including sideroblastic anemias, porphyria, and defects of iron absorption transport, utilization and recycling
    • Inflammation or chronic disease
    • Lead poisoning

Signs and Symptoms

  • Primary symptoms include: Dyspnea (exertional or at rest), fatigue, palpitations, headache, faintness or lightheadedness, tinnitus, anorexia, gastrointestinal (GI) disturbances, loss of libido
  • Symptoms of severe anemia include: Lethargy, confusion, tachycardia, retinal hemorrhage that may lead to life-threatening complications such as congestive heart failure, angina, arrhythmia and/or myocardial infarction
  • Symptoms can be due to decreased oxygen delivery to tissues and in patients with acute and marked bleeding, the added insult of hypovolemia
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
5 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.